Yttrium is a metal of the rare earth group of elements. A radioactive form of yttrium may be attached to a monoclonal antibody or other molecule that can locate and bind to cancer cells and be used to diagnose or treat some types of cancer.
An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.
MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
Molecular Insight Pharmaceuticals, Inc. today announced that it has completed an agreement to sub-license its Onalta™ brand 90-Y edotreotide radiotherapeutic in certain countries in Europe, the Middle East, North Africa, Russia and Turkey to BioMedica Life Sciences, S.A., Athens, Greece.
Carbon nanotubes hold many exciting possibilities, some of them in the realm of the human nervous system. Recent research has shown that carbon nanotubes may help regrow nerve tissue or ferry drugs used to repair damaged neurons associated with disorders such as epilepsy, Parkinson's disease and perhaps even paralysis.
The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.
Duke University and United States Army scientists have found that a cheap and nontoxic sunburn and diaper rash preventative can be made to produce brilliant light best suited to the human eye.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
Liver cancer specialists at Jefferson's Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new treatment for liver cancer.
High-tech dental lasers used mainly to prepare cavities for restoration now can help eliminate bacteria in root canals, according to research published in the July issue of The Journal of the American Dental Association (JADA).
Immunomedics has reported in an oral presentation at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) that the antigen targeted by the humanized PAM4 antibody is expressed in early stage pancreatic cancer specimens, a stage before the tumor becomes invasive.
Magnetic iron oxide nanoparticles have already proven their utility for imaging metastatic breast cancer lesions in sentinel lymph nodes, and numerous groups are attempting to use iron nanoparticles in other imaging applications.
The University Hospital at the University of Navarra is the only centre throughout the entire Spanish state for the treatment of liver tumours by means of radioembolisation and the one with the greatest accumulated experiences in the treatment throughout Europe.
Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.
According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor.
A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.
Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).